MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
0.2330
-0.0050
-2.10%
After Hours: 0.2550 +0.022 +9.44% 19:50 02/13 EST
OPEN
0.2580
PREV CLOSE
0.2380
HIGH
0.2588
LOW
0.2330
VOLUME
135.49K
TURNOVER
--
52 WEEK HIGH
1.730
52 WEEK LOW
0.2178
MARKET CAP
10.67M
P/E (TTM)
-0.3976
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AKTX last week (0209-0213)?
Weekly Report · 18h ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 3d ago
Akari Therapeutics CEO Highlights ADC Pipeline Expansion in Virtual Investor Interview
Reuters · 5d ago
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline
Barchart · 5d ago
Weekly Report: what happened at AKTX last week (0202-0206)?
Weekly Report · 02/09 10:32
Akari Therapeutics to Present Next-Generation ADC Platform at Webull Financial Virtual Conference
Reuters · 02/05 14:15
Akari Therapeutics präsentiert sich auf der virtuellen Corporate Connect Webinar Series von Webull Financial
Reuters · 02/05 14:15
Weekly Report: what happened at AKTX last week (0126-0130)?
Weekly Report · 02/02 10:32
More
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

Webull offers Akari Therapeutics PLC (ADR) stock information, including NASDAQ: AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.